Share Name Share Symbol Market Type Share ISIN Share Description
Scapa Group Plc LSE:SCPA London Ordinary Share GB0007281198 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  -6.60 -3.59% 177.00 299,669 16:29:59
Bid Price Offer Price High Price Low Price Open Price
177.00 178.20 185.00 177.00 185.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 311.80 14.90 5.30 33.4 332
Last Trade Time Trade Type Trade Size Trade Price Currency
17:47:29 O 96 177.00 GBX

Scapa (SCPA) Latest News

More Scapa News
Scapa Investors    Scapa Takeover Rumours

Scapa (SCPA) Discussions and Chat

Scapa Forums and Chat

Date Time Title Posts
18/12/202020:54Scapa onwards and upwards1,933
05/10/200614:18Scapa.......nobrainer or should I scarper?76
16/3/200613:43SCAPA upwards147

Add a New Thread

Scapa (SCPA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Scapa trades in real-time

Scapa (SCPA) Top Chat Posts

Scapa Daily Update: Scapa Group Plc is listed in the Chemicals sector of the London Stock Exchange with ticker SCPA. The last closing price for Scapa was 183.60p.
Scapa Group Plc has a 4 week average price of 172.20p and a 12 week average price of 117.20p.
The 1 year high share price is 295p while the 1 year low share price is currently 82.70p.
There are currently 187,811,037 shares in issue and the average daily traded volume is 211,029 shares. The market capitalisation of Scapa Group Plc is £332,425,535.49.
robow: Scapa is a value recovery play, says Jefferies Chemicals group Scapa (SCPA), which specialises in chemicals for healthcare such as wound sealant, is a ‘value recovery play’, according to Jefferies. Analyst Kit Lee retained his retained his ‘buy’ recommendation and target price of 150p on the shares, which rose 8.4% to 133.8p yesterday after the company said half-year revenues would top expectations. ‘While second-half 2021 will likely still see impact from Covid-19, end-market demand is recovering in various segments and should normalise in full-year 2021/22,’ Lee said. ‘Longer term, we believe healthcare is well positioned to drive upside with the development pipeline and asset acquisitions. With shares trading at 11 times current year 2022 price-earnings, we view Scapa as a value recovery play.’
babycheeky: Never ceases to amaze me that you still try to deny you were discodave4 before starting your new handle discodave45 and posts on many of the same boards. Well dave seems to be a pattern ! DiscoDave4 - 31 May 2020 - 10:22:52 - 1711 of 1876 Scapa onwards and upwards - SCPA No problem. Apologies if link doesn’t work for everyone, for some reason they don’t always work, perhaps down to using the ADVFN app via an IPad. He doesn’t say a lot really but he has his followers.
babycheeky: seems to be a pattern ! DiscoDave4 - 31 May 2020 - 10:22:52 - 1711 of 1876 Scapa onwards and upwards - SCPA No problem. Apologies if link doesn’t work for everyone, for some reason they don’t always work, perhaps down to using the ADVFN app via an IPad. He doesn’t say a lot really but he has his followers.
babycheeky: DiscoDave4 - 01 Jun 2020 - 09:09:49 - 1714 of 1875 Scapa onwards and upwards - SCPA He admits he is erratic with some of his trades but he generally is a very successful stock picker.
babycheeky: odd that discodave4 likes this one and discodave45 does DiscoDave4 - 02 Jun 2020 - 10:44:37 - 1721 of 1874 Scapa onwards and upwards - SCPA Pmsl
discodave45: Hope this doesn't repeat June's share price profile.
smithless: Scuba- if they do I will be buying bucket loads. Share price depressed due to slow return to normalised trading due to Covid - all outlined in audited accounts. Depressing for those who are in, but will recover quite swiftly nxt year. Just looked at the case with Convatec and Convatec in its report and accounts under contingent liabilities fails to mention anything about its claim against Scapa being dismissed in New Jersey?!? nor that it has had to put in a new claim against Scapa? Looks like Convatec on the run a bit here.
discodave45: Just checked and issued shares have increased by about 25% since March 2015, FY year end eps in 2015 was 9p and the share price was circa £2 (PE 22). Recent prelims gave adjusted eps of 12.4p which normalised to 2015 issued share capital is equivalent to eps of about 16p (22 = £3.50), so the market appears to be suggesting a crash to circa 3p eps for 2020/21.......crazy!.
discodave45: It's back to 2013 levels.They haven't archived annual results for March 2013 on their website but comparisons with 2015 when the share price was £2 is as follows:Rev 2015 £236m, 2020 £321m (+36%)Trading profit 2015 £18m, 2020 £28m (+56%)Adjusted eps 2015 9p, 2020 12.4p (+38%). Don't know if number of issued shares have changed since 2015, but it appears on the face of it to be well undervalued.Don't know what the forecasts are for this year but from memory brokers have 12p eps for 2021/22 (on a par with 2019/20), so again based on 2015 this should be in excess of £2 and is currently only on a forward (21/22) pe of about 7.A share that continues to baffle me! :)
cyberian: I would love to see a company like Bunzl make an early bid for SCPA...their medical distribution arm saw excellent growth/earnings in their results last week, and they could well afford to buy. Whatever, I expect that the results due in about 10 days will be OK, and better prospects going forward into the following year...hopefully, this projected growth will move the share price up to more realistic levels as seen in the past. Currently a pretty good level to buy, with fairly limited downside, however, just a personal view.
Scapa share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210115 19:10:23